WO2017183655A1 - 培養上皮シートの製造方法 - Google Patents
培養上皮シートの製造方法 Download PDFInfo
- Publication number
- WO2017183655A1 WO2017183655A1 PCT/JP2017/015704 JP2017015704W WO2017183655A1 WO 2017183655 A1 WO2017183655 A1 WO 2017183655A1 JP 2017015704 W JP2017015704 W JP 2017015704W WO 2017183655 A1 WO2017183655 A1 WO 2017183655A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- epithelial
- serum
- cell sheet
- comecs
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
- C12N5/0632—Cells of the oral mucosa
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/38—Stomach; Intestine; Goblet cells; Oral mucosa; Saliva
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3641—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the site of application in the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/34—Sugars
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/35—Polyols, e.g. glycerin, inositol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/11—Epidermal growth factor [EGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/117—Keratinocyte growth factors (KGF-1, i.e. FGF-7; KGF-2, i.e. FGF-12)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/38—Hormones with nuclear receptors
- C12N2501/39—Steroid hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases (EC 2.)
- C12N2501/727—Kinases (EC 2.7.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/90—Polysaccharides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/90—Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
- C12N2533/92—Amnion; Decellularised dermis or mucosa
Definitions
- the present invention mainly relates to a method for producing a cultured epithelial sheet.
- Non-Patent Document 1 A method for producing cultured epithelial sheets (COMECS) used for corneal regenerative medicine has been reported (Patent Document 1, Non-Patent Documents 1 to 3).
- the cultured epithelial sheet obtained by this method has been utilized for the treatment of intractable keratoconjunctival diseases, and has a high treatment record.
- “cultured autologous oral mucosal epithelial sheet transplantation” (Cultivated Oral Mucosal Epithelial Sheet Transplantation (COMET)) is practiced as an advanced medical treatment.
- COMET Cultured autologous oral mucosal epithelial sheet transplantation
- Nakamura T Endo K, Cooper LJ et al. Investigative ophthalmology & visual science 2003; 44: 106-116.
- Nakamura T Inatomi T, Sotozono C et al.
- Nakamura T Takeda K, Inatomi T et al.
- a conventionally known method for producing cultured epithelium uses mouse-derived 3T3 feeder cells and fetal bovine serum.
- mouse-derived 3T3 feeder cells and fetal bovine serum it is necessary to remove foreign substances from the culture system. Therefore, the present inventor tried to develop a culture method (culture technique) that does not use feeder cells and serum.
- the present inventor has conducted intensive studies to solve the above-mentioned problems, and surprisingly, there has been no surprise including (i) EGF protein or KGF protein, (ii) B-27 supplement, and (iii) ROCK inhibitor. It has been found that the above problems can be solved by using a serum medium. The present invention has been completed by further studies based on such findings.
- the present invention includes the inventions of the following aspects.
- Item 1 A method for producing an epithelial cell sheet comprising culturing cells derived from oral mucosal epithelial cells on a substrate in a serum-free medium, wherein the serum-free medium comprises (i) EGF protein or KGF protein, A method which is a serum-free medium comprising (ii) a B-27 supplement, and (iii) a ROCK inhibitor.
- the medium is (Iv) polysaccharides
- Item 4 (i) EGF protein or KGF protein, (Ii) A serum-free medium for producing an epithelial cell sheet using cells derived from oral mucosal epithelial cells as a material, comprising a B-27 supplement and (iii) a ROCK inhibitor.
- the present invention provides a culture method that does not use feeder cells and serum. Moreover, the cultured epithelial sheet provided by the present invention has excellent properties for use in the treatment of intractable keratoconjunctival diseases. According to the present invention, it is possible to further improve the treatment technique for intractable keratoconjunctival disease.
- phase contrast microscopic image of COMECS (cultivated ivatoral mucosal epithelial cell sheet) and the result of histological examination are shown.
- AC Phase contrast microscopic image on day 7 of culture
- DF Cross section of COMECS stained with HE (hematoxylin and eosin), bright field micrograph: asterisk indicates denuded amniotic membrane.
- GI Schematic diagram of culture conditions. Bar: 100 ⁇ m. The evaluation result of colony formation efficiency is shown.
- AD Representative examples of colony forming plates of oral mucosal epithelial cells by control and FFSF culture and phase contrast microscopic images.
- E Measurement result of colony formation efficiency.
- F Measurement results of cell number.
- the gene expression profile of FFSF COMECS is shown by principal component analysis (Principal component analysis (PCA)).
- PCA Principal component analysis
- An antibody-stained image (Marker) and a nucleus (PI (propidium iodide) -stained image) are shown separately.
- FIG. 4B-F are black and white reversal images.
- An antibody-stained image of K12 and a nucleus (PI (propidiumideiodide) -stained image) are shown separately.
- FIG. 5G-I is a black and white reversal image.
- An antibody-stained image of p75 and a nucleus (PI (propidium iodide) -stained image) are shown separately.
- FIG. 6G is a black and white inverted image. 6J-O black and white reversal image.
- An antibody-stained image (Marker) and a nucleus (PI (propidium iodide) -stained image) are shown separately.
- the serum-free medium of the present invention is (I) EGF protein or KGF protein, It comprises (ii) a B-27 supplement, and (iii) a ROCK inhibitor.
- a known serum-free medium particularly a serum-free medium for use in culturing stem cells can be used.
- MEM medium Minimum Essential Medium
- DMEM Dulbecco's modified Eagle's medium
- Ham F12 medium Ham's F12 medium
- BME medium Basal Medium Eagle
- IMDM medium Iscove's Modified Dulbecco's medium
- Roswell® Park® Memorial® Institute Defined® Keratinocyte-SFM (Defined® Keratinocyte® Serum® Free® Medium), and mixed media thereof.
- the growth factor EGF (epidermal growth factor) protein or KGF (keratinocyte growth factor) protein are both known proteins. From the viewpoint of not using a heterogeneous substance, it is preferably derived from a human.
- a recombinant protein (recombinant protein) can be used as the EGF protein or the KGF protein.
- the compounding amount of EGF (epidermal growth factor) protein or KGF (keratinocyte growth factor) protein is a final concentration of about 1-100 ng / ml, preferably about 2-50 ng / ml, more preferably 5-20 ng / ml. It can be about ml.
- B-27 (trademark) supplement is a known serum-free supplement, and a commercially available product can be used.
- B-27 supplements are known to be added to a medium used for culturing and maintaining nerve cells.
- B-27 supplements are biotin, L-carnitine, corticosterone, ethanolamine, D (+) galactose, reduced glutathione, linoleic acid, linolenic acid, progesterone, putrescine, retinylacetic acid, selenium, triodo-1-tyromine, Contains vitamin E, vitamin E acetate, bovine albumin, catalase, insulin, superoxide dismutase, and transferrin.
- B-27 (trademark) supplement is added at a final concentration of about 0.2 to 20% (w / v), preferably about 0.5 to 10% (w / v), more preferably 1 to 5% (w / v). v) can be about.
- the ROCK inhibitor is not particularly limited as long as it is a compound that specifically inhibits the function of Rho-binding kinase (ROCK).
- ROCK Rho-binding kinase
- Y27632 ((R)-(+)-trans-N- (4-pyridyl) -4- (1-aminoethyl) -cyclohexanecarboxamide)
- Y39983 (R)-(+)-N- (4-1H- pyrrolo [2,3-b] pyridin-yl) -4- (1-aminoethyl) -benzamide
- fasudyl hydrochloride (1- (5-Isoquinolinesulfonyl) homopiperazine Hydrochloride) and the like.
- the blending amount of the ROCK inhibitor can be about 1 to 100 ⁇ M / L, preferably about 2 to 50 ⁇ M / L, and more preferably about 5 to 20 ⁇ M / L in the final concentration.
- the serum-free medium of the present invention can further contain catechins.
- catechins include catechin, epicatechin, gallocatechin, epigallocatechin, epicatechin gallate, epigallocatechin gallate and the like. Of these, epigallocatechine gallate is preferred.
- the blending amount in the final concentration can be about 0.5 to 100 mg / ml, preferably about 1 to 50 mg / ml, more preferably about 2 to 20 mg / ml.
- the serum-free medium of the present invention can further contain a polysaccharide.
- the polysaccharide include dextran, cellulose, mannan, starch, and agarose. Among them, dextran (for example, Dextran 40 having an average molecular weight of about 40,000) is preferable.
- the blending amount can be about 0.1 to 20% (w / v), preferably about 0.2 to 10% (w / v), and about 0.5 to 5% (w / v) at the final concentration.
- the serum-free medium of the present invention can further contain a corticoid.
- the corticoid include cortisone, hydrocortisone, cortisosterone and the like. Of these, hydrocortisone is preferred.
- the blending amount in the final concentration can be about 0.01 to 5% (w / v), preferably about 0.05 to 2% (w / v), and about 0.1 to 1% (w / v).
- the serum-free medium of the present invention can contain arbitrary components other than the above.
- components commonly used in a stem cell culture medium such as a buffer, inorganic salts, antibiotics (eg, one or more of penicillin, kanamycin, streptomycin, etc.) can be contained.
- % (w / v) indicates a weight capacity percentage.
- % (V / v) indicates a volume percentage.
- the epithelial cell sheet of the present invention can be produced in the same manner as the method for producing an epithelial sheet for use in known COMET, except that the above serum-free medium is used.
- the method for producing an epithelial field cell sheet of the present invention specifically includes a step of culturing cells derived from oral mucosal epithelial cells on a substrate in the serum-free medium of the present invention.
- culture in the presence of so-called feeder cells is not performed.
- protein components such as serum components are not added to the medium.
- Oral mucosal epithelial-derived cells are cells that can be collected from, for example, oral mucosal epithelium, lip, palate, and cheek cells. Preferably, it contains oral mucosal epithelial stem cells and / or oral mucosal epithelial progenitor cells.
- Oral mucosal epithelial-derived cells may be derived from the recipient of the epithelial cell sheet (autologous cells) or may be derived from other individuals (autologous cells). From the viewpoint that rejection can be reduced, it is preferably an autologous cell.
- Oral mucosal epithelial cells are preferably subjected to treatment with an enzyme such as dispase or trypsin, or filter treatment in order to remove impurities such as connective tissue.
- an enzyme such as dispase or trypsin, or filter treatment in order to remove impurities such as connective tissue.
- the substrate is not particularly limited as long as it can be a substrate of the epithelial cell sheet.
- a membrane containing collagen as a main component can be used as the base material.
- the basement membrane is an amniotic membrane or an amnion from which the epithelium has been removed.
- the amnion from which the epithelium has been removed is known and can be produced, for example, according to the description of the literature: Koizumi N et al. Invest Ophthalmol Vis Sci. 2000 Aug; 41 (9): 2506-13.
- An epithelial cell sheet is formed on the substrate by subjecting cells derived from the oral mucosa epithelium to culture on the substrate.
- Cells derived from the oral mucosal epithelium have, for example, a cell density of about 1 ⁇ 10 3 cells / cm 2 or more, preferably about 1 ⁇ 10 3 cells / cm 2 to about 1 ⁇ 10 7 cells / cm 2 , more preferably about 1 It is preferable to seed on the substrate so that the density is from 10 4 / cm 2 to about 1 ⁇ 10 6 / cm 2 .
- the culture can be performed by a technique known to those skilled in the art, for example, using the serum-free medium.
- suitable culture techniques include a technique of culturing under conditions of about 37 ° C. and a carbon dioxide concentration of about 5 to 10% (v / v), but is not limited thereto. Cultivation under the above conditions can be performed using, for example, a known CO 2 incubator.
- the culture period can be, for example, about 7 days to 3 weeks.
- the culture method of the present invention preferably includes a step of temporarily exposing the outermost layer of the cell layer to the outside of the culture solution so that the obtained epithelial cell sheet is composed of the layered cell layer.
- the outermost layer of the cell layer can be temporarily exposed outside the culture solution by temporarily removing a part of the culture solution or lifting the cell layer together with the basement membrane.
- the time for contacting the outermost layer of the cell layer with air can be, for example, about 3 days to 2 weeks, preferably within 1 week, more preferably within 3 days.
- the epithelial cell sheet obtained by the culture method of the present invention can be used as a transplant material for patients with intractable keratoconjunctival diseases.
- refractory keratoconjunctive diseases include diseases in which corneal epithelial stem cells are irreversibly dysfunctional or disappear, such as Stevens-Johnson syndrome, pemphigoid, and alkaline corrosion.
- a scar tissue is incised at the corneal ring of a keratoconjunctival disease patient. Subsequently, after removing the scar conjunctiva tissue that has invaded the cornea to expose the corneal stroma, a corneal epithelial sheet is sewn slightly inside the ring portion.
- This method is the same as COMET, which has a high treatment record, and it is expected that the method can be performed very stably.
- the epithelial cell sheet obtained by the culture method of the present invention can detect the expression of an epithelial stem cell marker (for example, p75 neurotrophineceptreceptor: p75NTR, CD271) and a proliferative cell marker (for example, Ki76), as shown in Examples below. It is considered that there are cells that maintain the characteristics as stem cells. Corneal epithelial cell markers (eg, keratin 12, keratin 3) as well as expression can be detected. The gene expression pattern is also more similar to corneal epithelial cells than known epithelial cell sheets. Since it has such characteristics, it has high utility as a transplant material for patients with intractable keratoconjunctival diseases.
- an epithelial stem cell marker for example, p75 neurotrophineceptreceptor: p75NTR, CD271
- Ki76 proliferative cell marker
- the obtained oral mucosal epithelial cells (1-2 ⁇ 10 5 cell / ml) were seeded on a denuded amniotic membrane (AM) (amniotic collagen sheet) spread on a culture insert.
- AM amniotic membrane
- composition of the medium of the FFSF (feeder-free and serum-free) system of the present invention was as follows.
- FFSF feeder-free and serum-free
- EGF EGF
- Rho-associated protein kinase (ROCK) inhibitor Y-27632 1 ⁇ l / ml) (Abcam Plc., Cambridge, MA) B27 (2% (w / v)) (Life Technologies)
- hydrocortisone (1 ⁇ l / ml) (Lonza)
- -)-EPIGALLOCATECHINE GALLATE 10ng / ml) (Sigma-Aldrich, St. Louis, MO) Dextoran40 (1% (w / v)) (Tokyo Kasei Kougyou, Tokyo) Penicillin-Streptomycin (50IU / ml) (Life Technologies).
- composition was also cultured.
- KSFM K-SFM
- Control 2 KGM + 3T3 (Control)
- Culture medium keratinocyte growth medium KGM: ArBlast Co., Ltd., Kobe, Japan
- Additive ingredients 5% (w / v)
- FBS Fetal bovine serum
- Feeder cell co-culture
- NIH-3T3 fibroblasts inactivated with mitomycin C (MMC)
- Fig. 1 shows culture results (Figs. 1A to F) and schematic diagrams of culture schemes (Figs. 1G to I).
- Colony forming efficiency (Colony-forming efficiency, CFE) was evaluated for the cells constituting the acquired epithelial cell sheet.
- FIGS. 3G, H, arrow The results of co-staining with Propidium iodide (nuclear staining) are shown in FIGS.
- ZO-1 Fig. 3G, H, arrow
- Fig. 3G, H, arrow a tight junction-related factor in apical cells
- Desmoplakin Fig. 3I, J
- Fig. 3K-N Desmoplakin
- Fig. 3K-N Oral mucosal epithelial-specific Keratin13 (K13) and corneal-specific Keratin3 (K3)
- Ki67 Ki67, a marker of cells that are actively proliferating cells (Fig. 3S) , T), and p75 (FIG. 3U, V), which is a marker for oral mucosal epithelial stem / progenitor cells.
- FFSF COMECS has cell binding, basement membrane constituent protein, differentiation ability, proliferation ability, and stem cell ability which are considered to be essential properties for clinical application and application.
- the primers used are as follows.
- corneal epithelial markers K12 is highly reliable as a specific marker.
- Other corneal epithelial markers include K3, ALDH3 and TKT.
- KFF expression could be detected in FFSF COMECS, but not in Control COMECS.
- K3, ALDH3 and TKT which are corneal epithelial markers
- p75 which is a stem / progenitor cell marker
- FIGS. 4B to 4E The results are shown in FIGS. 4B to 4E. It was revealed that human oral mucosal epithelial cells (in ⁇ ⁇ vivo) and Control COMECS do not express K12 (FIGS. 4B and 4C). On the other hand, in FFSF COMECS, expression of K12 could be observed locally and sporadically (FIG. 4F).
- the expression pattern of K12 in FFSFSCOMECS may be different from the corneal epithelium (inovivo) and the corneal epithelial cell culture sheet (Control) by the conventional method (FIGS. 4C and E).
- holoclone is typically large and smooth around the original clone, mainly containing small cells.
- holoclone formed large colonies that grew rapidly, and 5% or less of the cells were terminally differentiated (FIGS. 5A and 5D).
- Paraclone is typically a small original clone and contains mainly large differentiated cells. No colonies formed on the plate or uniformly formed small terminal colonies (terminal colonies) (FIGS. 5C and F).
- meroclone exhibits intermediate properties between holoclone and paraclone. Both growing and non-growing colonies formed on the plate (FIGS. 5B, E).
- p75 in each clonal type was verified by immunohistochemical analysis. p75 is strongly expressed in the cell membrane of holoclone cells (Fig. 5G), and moderately expressed in the cell membrane of some small cells of meloclone cells (Fig. 5H), but rarely in paraclone cells. Expression could not be confirmed (FIG. 5I).
- the epithelial cell sheet prepared by COMECS xenograft surgery was prepared according to the description of the literature: Kobayashi M, Nakamura T, Yasuda M et al. Stem cells translational medicine 2015; 4: 99-109. Xenografts.
- transplanted COMECS adhered well to the host tissue, and cell infiltration into the subepithelium was not observed (FIGS. 6H and I). It was confirmed by hematoxylin-eosin staining that the transplanted COMECS was well stratified and contained differentiated cells (FIGS. 6H and I). Staining with an anti-human nuclear antibody was performed to confirm the presence of the transplanted human COMECS (FIG. 6G).
- transplanted cells maintained the proliferation ability and the characteristics as stem / progenitor cells on the rabbit cornea surface, and the prepared FFSFECCOMECS can be successfully applied to in vivo. Later, it was found that the visual function was maintained well.
- GCOS GeneChip operating software
- Fig. 7 shows the result of Principal component analysis (PCA) mapping. It was revealed that the gene expression profile in human corneal epithelium in vivo is very different from that of human oral mucosa epithelium. In both the epithelial cell sheet (FFSF COMECS) and the control epithelial cell sheet (Control COMECS) of the present invention, the gene expression profile was located between the human corneal epithelium and the human oral mucosal epithelium. Of these, FFSF COMECS tended to be closer to the human corneal epithelium than Control COMECS. This result suggests that the method of the present invention affects the integrity and properties of epithelial cells.
- PCA Principal component analysis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Dermatology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Transplantation (AREA)
- Botany (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Immunology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
(i)EGFタンパク質またはKGFタンパク質、
(ii)B-27サプリメント、及び
(iii)ROCK阻害剤
を含む無血清培地である、方法。
(iv)多糖類、
(v)カテキン類、及び
(vi)コルチコイド
からなる群から選択される少なくとも1種をさらに含む請求項1に記載の方法。
(ii)B-27サプリメント、及び
(iii)ROCK阻害剤
を含む、口腔粘膜上皮細胞由来の細胞を材料として上皮細胞シートの製造するための無血清培地。
(i)EGFタンパク質またはKGFタンパク質、
(ii)B-27サプリメント、及び
(iii)ROCK阻害剤
を含むことを特徴とする。
<材料>
口腔組織は、提供ボランティアから及び口腔外科手術を受けた患者由来の余剰組織として取得した。すべての試料は採取後1~2時間以内に処理をした。
<培養>
口腔粘膜上皮細胞を、公知の方法に従って培養した(非特許文献1~3)。
・培地
幹細胞用培地
・添加成分
recombinant human EGF (10ng/ml) (Life Technologies)
Rho-associated protein kinase (ROCK) inhibitor Y-27632 (1μl/ml) (Abcam Plc., Cambridge, MA)
B27 (2%(w/v)) (Life Technologies)
hydrocortisone (1μl/ml) (Lonza)
(-)-EPIGALLOCATECHINE GALLATE (10ng/ml) (Sigma-Aldrich, St. Louis, MO)
Dextoran40 (1%(w/v)) (Tokyo Kasei Kougyou, Tokyo)
Penicillin-Streptomycin (50IU/ml) (Life Technologies)。
・培地
幹細胞用培地:defined K-SFM (Life Technologies)
・添加成分
添付のconcomitant supplement。
・培地
keratinocyte growth medium (KGM: ArBlast Co., Ltd., Kobe, Japan)
・添加成分
5%(w/v) FBS(Fetal bovine serum、ウシ胎児血清)(Hyclone, Tauranga, New Zealand)
・フィーダー細胞(Feeder cell)(共培養)
NIH-3T3 fibroblasts(mitomycin C(MMC)による不活化処理済み)。
取得した上皮細胞シートを構成する細胞について、コロニー形成効率(Colony-forming efficiency、CFE)を評価した。
取得した上皮細胞シートの形態を透過電子顕微鏡観察に供した。
取得した上皮細胞シートに対して、各種マーカーの抗体染色を行った。
RT-PCR法により、下記遺伝子の発現解析を行った。
本発明の方法で得た上皮細胞シートについて、クローナル解析(clonal analysis)を行った。解析は、文献:Barrandon Y, Green H. Proceedings of the National Academy of Sciences of the United States of America 1987; 84:2302-2306.の記載に準じて行った。
作製した上皮細胞シートを、文献:Kobayashi M, Nakamura T, Yasuda M et al. Stem cells translational medicine 2015; 4:99-109.の記載に準じて、Albinoウサギ(2-2.5kg)に異種移植した。
本発明の上皮細胞シート(FFSF COMECS)、対照上皮細胞シート(Control COMECS)、角膜上皮(HC in vivo)、及び口腔粘膜上皮(HO in vivo)のそれぞれについて、Total RNAを抽出しcDNAを調整し、GeneChip Human Genome U133 Plus 2.0 (Affymetrix, Santa Clara, CA)を用いて遺伝子発現プロファイルの解析を行った。アレイデータ解析は、Affymetrix GeneChip operating software (GCOS) version 1.0を使用した。
Claims (4)
- 口腔粘膜上皮細胞由来の細胞を、無血清培地中、基材上で培養する工程を含む上皮細胞シートの製造方法であって、前記無血清培地が
(i)EGFタンパク質またはKGFタンパク質、
(ii)B-27サプリメント、及び
(iii)ROCK阻害剤
を含む無血清培地である、方法。 - 上記培地が、
(iv)多糖類、
(v)カテキン類、及び
(vi)コルチコイド
からなる群から選択される少なくとも1種をさらに含む請求項1に記載の方法。 - 請求項1または2に記載の方法により得られる上皮細胞シート。
- (i)EGFタンパク質またはKGFタンパク質、
(ii)B-27サプリメント、及び
(iii)ROCK阻害剤
を含む、口腔粘膜上皮細胞由来の細胞を材料として上皮細胞シートの製造するための無血清培地。
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201780037143.1A CN109312301B (zh) | 2016-04-20 | 2017-04-19 | 用于制备培养上皮细胞片的方法 |
JP2018513195A JP7024974B2 (ja) | 2016-04-20 | 2017-04-19 | 培養上皮シートの製造方法 |
US16/095,173 US11479754B2 (en) | 2016-04-20 | 2017-04-19 | Method for producing cultivated epithelial cell sheet |
SG11201809235QA SG11201809235QA (en) | 2016-04-20 | 2017-04-19 | Method for producing cultivated epithelial cell sheet |
EP17785993.1A EP3447126A4 (en) | 2016-04-20 | 2017-04-19 | PROCESS FOR PRODUCING SHEET OF CULTIVATED EPITHELIAL CELLS |
KR1020187033340A KR102311121B1 (ko) | 2016-04-20 | 2017-04-19 | 배양 상피 시트의 제조 방법 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016084471 | 2016-04-20 | ||
JP2016-084471 | 2016-04-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017183655A1 true WO2017183655A1 (ja) | 2017-10-26 |
Family
ID=60116062
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2017/015704 WO2017183655A1 (ja) | 2016-04-20 | 2017-04-19 | 培養上皮シートの製造方法 |
Country Status (7)
Country | Link |
---|---|
US (1) | US11479754B2 (ja) |
EP (1) | EP3447126A4 (ja) |
JP (1) | JP7024974B2 (ja) |
KR (1) | KR102311121B1 (ja) |
CN (1) | CN109312301B (ja) |
SG (1) | SG11201809235QA (ja) |
WO (1) | WO2017183655A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111836884A (zh) * | 2018-03-28 | 2020-10-27 | 国立大学法人大阪大学 | 源自干细胞的泪腺组织的制作方法 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110904028A (zh) * | 2019-12-04 | 2020-03-24 | 合肥中科干细胞再生医学有限公司 | 一种口腔黏膜上皮细胞皮片制备方法 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08243156A (ja) * | 1995-03-07 | 1996-09-24 | Menicon Co Ltd | 培養皮膚およびその製造法 |
JP2005229869A (ja) * | 2004-02-18 | 2005-09-02 | Satoshi Yamagami | ヒト角膜内皮細胞の培養物層積層体及びその作製方法 |
JP2010022327A (ja) * | 2008-07-23 | 2010-02-04 | Nippon Menaade Keshohin Kk | 幹細胞から分化誘導した角化細胞及び人工表皮シート |
JP2010046058A (ja) * | 2008-07-24 | 2010-03-04 | Two Cells Co Ltd | 治療用培養細胞の製造方法 |
WO2011021706A1 (ja) * | 2009-08-19 | 2011-02-24 | 国立大学法人東北大学 | 角膜移植用シート |
WO2015016371A1 (ja) * | 2013-07-30 | 2015-02-05 | 京都府公立大学法人 | 角膜内皮細胞マーカー |
WO2015068505A1 (ja) * | 2013-11-11 | 2015-05-14 | 住友化学株式会社 | 網膜色素上皮細胞の製造方法 |
JP2015155400A (ja) * | 2014-01-16 | 2015-08-27 | Jcrファーマ株式会社 | 角膜内皮細胞を含有する移植用組成物 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1454600B1 (en) * | 2001-11-19 | 2011-08-31 | ArBlast Co., Ltd. | Ectocornea-like sheet and method of constructing the same |
WO2006003818A1 (ja) | 2004-06-30 | 2006-01-12 | Alblast Co., Ltd. | 角膜上皮シート及びその作製方法 |
EP2177602B1 (en) | 2007-07-13 | 2013-09-11 | Mitsubishi Tanabe Pharma Corporation | Method for isolation of cell, serum-free culture medium for cell, and method for culture of cell |
EP2606126B1 (en) | 2010-08-19 | 2016-05-18 | F.Hoffmann-La Roche Ag | Conversion of somatic cells to induced reprogrammed neural stem cells (irnscs) |
CN103492555A (zh) * | 2011-04-20 | 2014-01-01 | 国立大学法人大阪大学 | 角膜上皮分化取向性iPS细胞 |
CN105308175B (zh) * | 2013-03-11 | 2018-09-21 | 日本化学研究株式会社 | 人角膜上皮片的制造法 |
SI2970890T1 (sl) | 2013-03-14 | 2020-10-30 | The Brigham And Women's Hospital, Inc. | Sestavki in postopki za razmnoževanje in kultiviranje epitelijskih matičnih celic |
CA2937129A1 (en) | 2014-01-17 | 2015-07-23 | Sumitomo Chemical Company, Limited | Method for manufacturing ciliary margin stem cells |
WO2016114285A1 (ja) * | 2015-01-15 | 2016-07-21 | 国立大学法人大阪大学 | 多能性幹細胞からの角膜上皮細胞の分化誘導 |
-
2017
- 2017-04-19 KR KR1020187033340A patent/KR102311121B1/ko active IP Right Grant
- 2017-04-19 CN CN201780037143.1A patent/CN109312301B/zh active Active
- 2017-04-19 WO PCT/JP2017/015704 patent/WO2017183655A1/ja active Application Filing
- 2017-04-19 EP EP17785993.1A patent/EP3447126A4/en active Pending
- 2017-04-19 SG SG11201809235QA patent/SG11201809235QA/en unknown
- 2017-04-19 JP JP2018513195A patent/JP7024974B2/ja active Active
- 2017-04-19 US US16/095,173 patent/US11479754B2/en active Active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08243156A (ja) * | 1995-03-07 | 1996-09-24 | Menicon Co Ltd | 培養皮膚およびその製造法 |
JP2005229869A (ja) * | 2004-02-18 | 2005-09-02 | Satoshi Yamagami | ヒト角膜内皮細胞の培養物層積層体及びその作製方法 |
JP2010022327A (ja) * | 2008-07-23 | 2010-02-04 | Nippon Menaade Keshohin Kk | 幹細胞から分化誘導した角化細胞及び人工表皮シート |
JP2010046058A (ja) * | 2008-07-24 | 2010-03-04 | Two Cells Co Ltd | 治療用培養細胞の製造方法 |
WO2011021706A1 (ja) * | 2009-08-19 | 2011-02-24 | 国立大学法人東北大学 | 角膜移植用シート |
WO2015016371A1 (ja) * | 2013-07-30 | 2015-02-05 | 京都府公立大学法人 | 角膜内皮細胞マーカー |
WO2015068505A1 (ja) * | 2013-11-11 | 2015-05-14 | 住友化学株式会社 | 網膜色素上皮細胞の製造方法 |
JP2015155400A (ja) * | 2014-01-16 | 2015-08-27 | Jcrファーマ株式会社 | 角膜内皮細胞を含有する移植用組成物 |
Non-Patent Citations (4)
Title |
---|
KINOSHITA, SHIGERU ET AL.: "Development of Cultivated Mucosal Epithelial Sheet Transplantation for Ocular Surface Reconstruction", ARTIFICIAL ORGANS, vol. 28, no. 1, 2004, pages 22 - 27, XP055431194 * |
MIYASHITA, HIDEYUKI ET AL.: "Long-Term Maintenance of Limbal Epithelial Progenitor Cells Using Rho Kinase Inhibitor and Keratinocyte Growth Factor", STEM CELLS TRANSLATIONAL MEDICINE, vol. 2, 2013, pages 758 - 765, XP055334387 * |
See also references of EP3447126A4 * |
YOKOO, SEIICHI ET AL.: "Human Coneal epithelial equivalents for Ocular Surface Reconstruction in a Complete Serum-Free Culture System Without Unknown Factors", INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, vol. 49, no. 6, June 2008 (2008-06-01), pages 2438 - 2443, XP009135442 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111836884A (zh) * | 2018-03-28 | 2020-10-27 | 国立大学法人大阪大学 | 源自干细胞的泪腺组织的制作方法 |
CN111836884B (zh) * | 2018-03-28 | 2023-07-25 | 国立大学法人大阪大学 | 源自干细胞的泪腺组织的制作方法 |
Also Published As
Publication number | Publication date |
---|---|
EP3447126A1 (en) | 2019-02-27 |
US20190169571A1 (en) | 2019-06-06 |
CN109312301A (zh) | 2019-02-05 |
JP7024974B2 (ja) | 2022-02-24 |
EP3447126A4 (en) | 2019-11-13 |
US11479754B2 (en) | 2022-10-25 |
CN109312301B (zh) | 2023-06-16 |
SG11201809235QA (en) | 2018-11-29 |
JPWO2017183655A1 (ja) | 2019-02-21 |
KR20180135015A (ko) | 2018-12-19 |
KR102311121B1 (ko) | 2021-10-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11001808B2 (en) | Immortalization of epithelial cells and methods of use | |
Kolli et al. | Successful application of ex vivo expanded human autologous oral mucosal epithelium for the treatment of total bilateral limbal stem cell deficiency | |
JP5227024B2 (ja) | 毛包真皮毛根鞘細胞の培養法 | |
US20120142103A1 (en) | Method for inducing differentiation into epithelial progenitor cell/stem cell population and corneal epithelial cell population from induced pluripotent stem cells | |
KR20170020527A (ko) | 배양된 포유동물 윤부 줄기세포, 이를 생성하는 방법, 및 이의 용도 | |
Sen et al. | Molecular characterization of explant cultured human oral mucosal epithelial cells | |
KR20070037451A (ko) | 각막 상피 시트 및 그 제조 방법 | |
KR20040072635A (ko) | 각막 상피형 시트, 및 그의 제조 방법 | |
Witt et al. | Decellularized porcine conjunctiva as an alternative substrate for tissue-engineered epithelialized conjunctiva | |
De Miguel et al. | Frontiers in regenerative medicine for cornea and ocular surface | |
WO2019139137A1 (ja) | 重層扁平上皮細胞の正常分化・成熟促進剤、上皮疾患治療剤及び重層扁平上皮細胞の正常分化・成熟促進方法 | |
JPWO2005087285A1 (ja) | 角膜上皮シート及びその作製方法、並びに同シートを用いる移植方法 | |
WO2017183655A1 (ja) | 培養上皮シートの製造方法 | |
Lu et al. | Conjunctival reconstruction with progenitor cell-derived autologous epidermal sheets in rhesus monkey | |
US10415014B2 (en) | Method for the ex vivo cultivation of oral mucosal epithelial progenitor cells and oral mucosal epithelial cells | |
JPWO2007091409A1 (ja) | 組織幹細胞由来フィーダー細胞 | |
Koike et al. | Cultured epithelial grafting using human amniotic membrane: the potential for using human amniotic epithelial cells as a cultured oral epithelium sheet | |
KR101970069B1 (ko) | 사람 하비갑개 유래 중간엽 줄기세포로부터 점막상피세포로의 분화방법 및 이의 용도 | |
JP2009225675A (ja) | 上皮系細胞シートの作製のための同種皮膚由来フィーダー細胞 | |
CN115786247A (zh) | 一种无血清培养基及其在维持毛囊活性、毛发养护及移植方面的应用 | |
Oliva et al. | Feeder cells free rabbit oral mucosa epithelial cell sheet engineering | |
US20090041822A1 (en) | Tissue transplant construct for the reconstruction of a human or animal organ | |
WO2024063020A1 (ja) | 椎間板治療剤 | |
JP4398290B2 (ja) | ヒト上皮細胞培養用培地 | |
WO2022098861A1 (en) | Compositions and methods for preparing reconstructed multilayered epithelial cell sheets |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref document number: 2018513195 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20187033340 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2017785993 Country of ref document: EP |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17785993 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2017785993 Country of ref document: EP Effective date: 20181120 |